Study on Structural Insights into Agonist Recognition and Function of the Thromboxane Receptor Published in Nature Communications

We are proud to announce that a new collaborative research article involving ATXA Therapeutics and our partners at Trinity College Dublin has been published this week in Nature Communications.

The paper, titled “Structural and Dynamic Insights into Agonist Recognition and Function of the Thromboxane A₂ Receptor”, presents cutting-edge findings on the structural determination and molecular dynamics of the thromboxane receptor (TP) – the cellular target of ATXA’s lead clinical candidate NTP42.

This work reflects the strength of ATXA’s ongoing scientific collaboration with researchers from the Schools of Medicine and Biochemistry & Immunology at Trinity College Dublin and our shared commitment to advancing fundamental understanding of the TP – a key target not only in pulmonary arterial hypertension (PAH), but more widely in other cardiopulmonary diseases and cardiometabolic disorders. It also underscores ATXA’s deep interest and involvement in the structural and functional biology of the TP that underpins our drug discovery efforts.

Read the full article here: https://www.nature.com/articles/s41467-026-69844-9.

We congratulate all authors and partners on this achievement and look forward to building on these insights as we progress NTP42 and our wider pipeline of TP antagonists in cardiopulmonary and related disease areas.